Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124337 | 1.00 | ELANE (0.68) | ELANECYP2C9CYP2C8CYP2C19CYP3A4 | |
| SCHEMBL2617951 | 0.93 | ELANE (0.74) | ELANECYP2C9CYP2C8CYP2C19CYP3A4 | |
| SCHEMBL15473046 | 0.93 | ELANE (0.64) | ELANECYP2C9CYP2C8CYP2C19 | |
| SCHEMBL124381 | 0.92 | ELANE (0.67) | ELANECYP2C9CYP2C8CYP2C19CYP3A4 | |
| SCHEMBL3718411 | 0.92 | ELANE (0.67) | ELANECYP2C9CYP2C8CYP2C19CYP3A4 | |
| SCHEMBL2617950 | 0.90 | ELANE (0.69) | ELANECYP2C9CYP2C8CYP2C19 | |
| SCHEMBL1134157 | 0.88 | ELANE (0.78) | ELANECYP2C9CYP2C8CYP2C19 | |
| SCHEMBL123237 | 0.88 | ELANE (0.78) | ELANECYP2C9CYP3A4 | |
| SCHEMBL126645 | 0.88 | ELANE (0.64) | ELANECYP2C9 | |
| SCHEMBL124338 | 0.88 | ELANE (0.64) | ELANECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| EP-2417112-B1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER IP GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2417112-B1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER IP GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-8691817-B2 | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2417112-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2010115548-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | TNNI3, TNNT2, PC | ELANE 1850/4885CYP2C9 581/4885CYP2C8 413/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | ELANE 1598/4885CYP2C9 582/4885CYP2C8 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.